OpenURL Connection Search

Select item for more details and to access through your institution.

Inhibiting Heat Shock Protein 90 (HSP90) Limits the Formation of Liver Cysts Induced by Conditional Deletion of Pkd1 in Mice.
Published in:
PLoS ONE, 2014, v. 9, n. 12, p. 1, doi. 10.1371/journal.pone.0114403
By:
- Smithline, Zachary B.;
- Nikonova, Anna S.;
- Hensley, Harvey H.;
- Cai, Kathy Q.;
- Egleston, Brian L.;
- Proia, David A.;
- Seeger-Nukpezah, Tamina;
- Golemis, Erica A.
Publication type:
Article
Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol.
Published in:
PLoS ONE, 2012, v. 7, n. 1, p. 1, doi. 10.1371/journal.pone.0029798
By:
- Blackman, Ronald K.;
- Cheung-Ong, Kahlin;
- Gebbia, Marinella;
- Proia, David A.;
- He, Suqin;
- Kepros, Jane;
- Jonneaux, Aurelie;
- Marchetti, Philippe;
- Kluza, Jerome;
- Rao, Patricia E.;
- Wada, Yumiko;
- Giaever, Guri;
- Nislow, Corey
Publication type:
Article
Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling.
Published in:
PLoS ONE, 2011, v. 6, n. 4, p. 1, doi. 10.1371/journal.pone.0018552
By:
- Proia, David A.;
- Foley, Kevin P.;
- Korbut, Tim;
- Jim Sang;
- Smith, Don;
- Bates, Richard C.;
- Yuan Liu;
- Rosenberg, Alex F.;
- Dan Zhou;
- Koya, Keizo;
- Barsoum, James;
- Blackman, Ronald K.
Publication type:
Article
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
Published in:
Investigational New Drugs, 2014, v. 32, n. 4, p. 577, doi. 10.1007/s10637-014-0095-4
By:
- He, Suqin;
- Smith, Donald;
- Sequeira, Manuel;
- Sang, Jim;
- Bates, Richard;
- Proia, David
Publication type:
Article
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Published in:
Investigational New Drugs, 2014, v. 32, n. 1, p. 14, doi. 10.1007/s10637-013-9971-6
By:
- Friedland, Julie;
- Smith, Donald;
- Sang, Jim;
- Acquaviva, Jaime;
- He, Suqin;
- Zhang, Chaohua;
- Proia, David
Publication type:
Article
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Published in:
Investigational New Drugs, 2012, v. 30, n. 6, p. 2201, doi. 10.1007/s10637-011-9790-6
By:
- Proia, David;
- Sang, Jim;
- He, Suqin;
- Smith, Donald;
- Sequeira, Manuel;
- Zhang, Chaohua;
- Liu, Yuan;
- Ye, Shuxia;
- Zhou, Dan;
- Blackman, Ronald;
- Foley, Kevin;
- Koya, Keizo;
- Wada, Yumiko
Publication type:
Article
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).
Published in:
FASEB Journal, 2018, v. 32, n. 5, p. 2735, doi. 10.1096/fj.201700909R
By:
- Nikonova, Anna S.;
- Deneka, Alexander Y.;
- Kiseleva, Anna A.;
- Korobeynikov, Vladislav;
- Gaponova, Anna;
- Serebriiskii, Ilya G.;
- Kopp, Meghan C.;
- Hensley, Harvey H.;
- Seeger-Nukpezah, Tamina N.;
- Somlo, Stefan;
- Proia, David A.;
- Golemis, Erica A.
Publication type:
Article
Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer.
Published in:
Clinical Colorectal Cancer, 2014, v. 13, n. 4, p. 207, doi. 10.1016/j.clcc.2014.09.001
By:
- Cercek, Andrea;
- Shia, Jinru;
- Gollub, Marc;
- Chou, Joanne F.;
- Capanu, Marinela;
- Raasch, Pamela;
- Reidy-Lagunes, Diane;
- Proia, David A.;
- Vakiani, Efsevia;
- Solit, David B.;
- Saltz, Leonard B.
Publication type:
Article
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Published in:
Targeted Oncology, 2015, v. 10, n. 2, p. 235, doi. 10.1007/s11523-014-0329-6
By:
- Smith, Donald;
- Acquaviva, Jaime;
- Sequeira, Manuel;
- Jimenez, John-Paul;
- Zhang, Chaohua;
- Sang, Jim;
- Bates, Richard;
- Proia, David
Publication type:
Article

Found: 9